CCM trades at Wall Street's consensus target of —.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CCM achieves its forward estimates and maintains a stable P/E multiple of 1.3x. This scenario reflects the blended consensus of 2 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 23, 2026, Concord Medical Services Holdings Limited (CCM) has a Wall Street consensus price target of N/A, based on estimates from 2 covering analysts. The company has a market capitalization of $779040.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is Buy, with 2 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CCM trades at a trailing P/E of -0.0x and forward P/E of 1.3x. Analysts expect EPS to grow +100.4% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
RDNTRadNet, Inc. | $4.4B | $55.76 | $85.00 | +58.2% | Buy | 104.2x | 11 |
USPHU.S. Physical Therapy, Inc. | $952M | $62.51 | $96.00 | +51.6% | Buy | 21.9x | 13 |
AMSFAMERISAFE, Inc. | $590M | $31.40 | $44.50 | +42.1% | Buy | 14.9x | 6 |
ARAYAccuray Incorporated | $37M | $0.31 | — | — | — | — | — |
MLABMesa Laboratories, Inc. | $515M | $93.23 | $94.00 | -1.2% | Hold | 10.5x | 8 |
ISRGIntuitive Surgical, Inc. | $143.1B | $402.95 | $597.78 | +47.0% | Buy | 38.9x | 55 |
MDTMedtronic plc | $101.8B | $79.27 | $95.80 | +20.7% | Buy | 13.3x | 51 |
EWEdwards Lifesciences Corporation | $49.5B | $85.88 | $96.55 | +10.5% | Buy | 29.0x | 48 |
SYKStryker Corporation | $116.7B | $304.64 | $387.46 | +25.9% | Buy | 20.5x | 51 |
HCAHCA Healthcare, Inc. | $84.3B | $376.99 | $504.73 | +34.5% | Buy | 12.4x | 46 |
Quick answers to the most common questions about buying CCM stock.
The consensus price target for CCM is $N/A, close to the current price of $5.35 (N/A% implied move). Based on 2 analyst estimates, the stock appears fairly valued near current levels.
CCM has a consensus rating of "Buy" based on 2 Wall Street analysts. The rating breakdown is predominantly bullish, with 2 Buy/Strong Buy ratings. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
With a forward P/E of 1.274x, CCM trades at a relatively low valuation. The consensus target of $N/A implies N/A% appreciation, suggesting the market may be pricing in risks.
The most bullish Wall Street analyst has a price target of $N/A for CCM, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. These targets typically reflect 12-month expectations.
CCM is lightly followed, with 2 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CCM stock forecast based on 2 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "Buy".
CCM trades at a forward P/E ratio of 1.3x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
CCM appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CCM analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.